Cholesterol metabolism reprogramming: shaping tumor immunity and immunotherapy
5 affiliations
- 1Department of Radiation Oncology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Hunan Cancer Hospital, Changsha, 410013 P. R. China
- 2Institute of Biochemistry and Molecular Biology, Guangdong Provincial Key Laboratory of Medical Immunology and Molecular Diagnostics, School of Basic Medical Sciences, Guangdong Medical University, Dongguan, 523808 P. R. China
- 3Department of Pathology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Hunan Cancer Hospital, Changsha, 410013 P. R. China
- 4Department of Gastroenterology, School of Medicine, The Affiliated Cancer Hospital of Xiangya, Central South University, Hunan Cancer Hospital, Changsha, 410013 P. R. China
- 5Hunan Key Laboratory of Translational Radiation Oncology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Hunan Cancer Hospital, Changsha, 410013 P. R. China
Abstract
Cholesterol, a vital biomolecule with essential physiological functions, undergoes frequent reprogramming of its metabolic pathways during tumorigenesis and progression. This reprogramming enables it to participate in immune regulation through multiple mechanisms. Accumulating evidence reveals the aberrant activation of cholesterol metabolic pathways across various malignancies. This dysregulation is characterized by enhanced synthesis, increased uptake, reduced efflux, and the accumulation of derivatives, such as cholesteryl esters and oxysterols. These alterations suggest that targeting cholesterol metabolism represents a promising strategy to enhance the efficacy of tumor immunotherapy. In cancer cells, reprogrammed cholesterol metabolism supports proliferation, stemness, and resistance to cell death, including ferroptosis and autophagy. Conversely, in immune cells, it modulates effector functions, polarization states, and the expression of immune checkpoints like PD-L1. Collectively, these effects shape an immunosuppressive tumor microenvironment that facilitates immune evasion. Furthermore, cholesterol metabolism intersects with critical oncogenic signaling pathways and is fine-tuned by non-coding RNAs, thereby further driving tumor progression and therapy resistance. This review systematically delineates the regulatory landscape of cholesterol homeostasis in both malignant and immune cells, highlighting its multifaceted impact on tumor immunity and therapeutic responses. A deeper understanding of cholesterol and its metabolite dynamics within the tumor microenvironment, as well as their crosstalk with other signaling networks, will not only aid in optimizing current immunotherapeutic approaches but also provide a crucial conceptual foundation for developing novel combination strategies.
Related
- The Y chromosome gene KDM5D restrains CD8+ T cell antitumor immunity through TCR and cholesterol-exhaustion programs
- Altered Cholesterol Metabolism in a Murine Model of Vertical Sleeve Gastrectomy
- Systemic tumor-cell reprogramming converts solid tumors into in situ biofactories for immunotherapy
- Editorial: Community series in unveiling the next generation of cancer immunity & immunotherapy in lung cancer, volume II
- Strategic engineering B cell immunity for cancer immunotherapy
BibTeX
@article{meng2026cholesterol,
title = {{Cholesterol metabolism reprogramming: shaping tumor immunity and immunotherapy}},
author = {Jing-Wen Meng and Yue-Tao Tan and Shan-Mei Chen and Ting Li and Hui Wang},
journal = {Journal of Experimental \& Clinical Cancer Research : CR},
year = {2026},
month = jul,
doi = {10.1186/s13046-026-03791-7},
url = {https://doi.org/10.1186/s13046-026-03791-7},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Cholesterol metabolism reprogramming: shaping tumor immunity and immunotherapy
AU - Jing-Wen Meng
AU - Yue-Tao Tan
AU - Shan-Mei Chen
AU - Ting Li
AU - Hui Wang
PY - 2026
DA - 2026/07/29
JO - Journal of Experimental & Clinical Cancer Research : CR
DO - 10.1186/s13046-026-03791-7
UR - https://doi.org/10.1186/s13046-026-03791-7
AB - Cholesterol, a vital biomolecule with essential physiological functions, undergoes frequent reprogramming of its metabolic pathways during tumorigenesis and progression. This reprogramming enables it to participate in immune regulation through multiple mechanisms. Accumulating evidence reveals the aberrant activation of cholesterol metabolic pathways across various malignancies. This dysregulation is characterized by enhanced synthesis, increased uptake, reduced efflux, and the accumulation of derivatives, such as cholesteryl esters and oxysterols. These alterations suggest that targeting cholesterol metabolism represents a promising strategy to enhance the efficacy of tumor immunotherapy. In cancer cells, reprogrammed cholesterol metabolism supports proliferation, stemness, and resistance to cell death, including ferroptosis and autophagy. Conversely, in immune cells, it modulates effector functions, polarization states, and the expression of immune checkpoints like PD-L1. Collectively, these effects shape an immunosuppressive tumor microenvironment that facilitates immune evasion. Furthermore, cholesterol metabolism intersects with critical oncogenic signaling pathways and is fine-tuned by non-coding RNAs, thereby further driving tumor progression and therapy resistance. This review systematically delineates the regulatory landscape of cholesterol homeostasis in both malignant and immune cells, highlighting its multifaceted impact on tumor immunity and therapeutic responses. A deeper understanding of cholesterol and its metabolite dynamics within the tumor microenvironment, as well as their crosstalk with other signaling networks, will not only aid in optimizing current immunotherapeutic approaches but also provide a crucial conceptual foundation for developing novel combination strategies.
SN - 0392-9078
SN - 1756-9966
ER -